Skip to main content

Carl D Regillo

Nov 9, 2026

1:40
What did these findings add to our understanding of treatment durability and disease control in everyday practice?
1:47
Well, we are learning a lot from real-world studies, and these are mostly large databases that are indicating mostly about how durable these drugs are, that is, furosemab and high-dose aflibrocept.
2:00
And it's all pointing in the same direction, and I'm going to ask you if you think that's what it's like in your experience as a practitioner, but it is...
2:09
Basically, what I'm seeing, which I'm seeing definitively more durability with these, we'll call them, quote, second-generation drugs.
2:18
But the data in particular presented at Retina Society pointed to mean or median durability in the maintenance phase, especially for wet AMD and also for DME to some degree, too, right in that 11, 12 weeks.
2:29
Mm-hmm.
2:31
When you compare that to what's been published in the past with the first generation drugs, standard dose, aflipracept, ranibizumab, they're more in the eight to nine weeks.

7 MINS LATER

9:12
What are your thoughts on the data that was presented at Retina Society, and how does that bear out in your own experience?
16:25
Before we get to it, just remind us how Lugana was structured.
16:29
Before we get to that, one more point about what EYP-1901 is, because it's more than just virolinib.
16:35
It's virolinib as a small molecule packaged in a bioerodible polymer that's injected intravitrally.
16:42
So this insert stays in the vitreous cavity and delivers therapeutic levels of the virolinib intravitrally for at least six months.
16:51
So it's sustained delivery, giving us indirectly an anti-FGF-like effect.
16:57
Now on to the clinical trials, because the clinical trial program in general for 1901 is large and robust, looking at both neovascular AMD and diabetic macrogema, both of which have been phased through testing successfully.
17:13
including the DAVIO-2 wet AMD study.
19:54
Can you talk us through that asymmetric cohort, help us define it and understand who was in that cohort?

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.